IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer

This is a Phase Ib/II study to evaluate the safety, tolerability and efficacy of IBI343 in combination with chemotherapy in patients with advanced pancreatic cancer, including a Phase Ib safety introduction and Phase II expansion phase. In phase Ib (safe introduction phase), participants with CLDN18.2-positive advanced pancreatic adenocarcinoma (PAC) who had previously received first-line gemcitabine-based systemic therapy were enrolled to receive IBI343 in combination with chemotherapy.A classic "3+3" dose-escalation design was used to determine the dose of the combination therapy, including

Trial Details

NCT ID
NCT07692750
Phase
PHASE1 / PHASE2
Sponsor
Zhejiang Cancer Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • IBI343+ capecitabine
  • IBI343+Capecitabine+oxaliplatin
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Sign a written Informed Consent Form (ICF) and be willing and able to comply with the visit and related procedures stipulated by the program.
  • Histopathologically confirmed unresectable locally advanced, recurrent, or metastatic PAC.
  • Progression or intolerance following first-line gemcitabine-based systemic therapy at locally advanced or recurrent/metastatic stages.If the time f…
  • The subject must not be suitable for radical treatment methods such as radical chemoradiotherapy and/or surgery.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →